RVL Pharmaceuticals Market Research Report

Company Overview

• Name: RVL Pharmaceuticals, Inc.

• Mission: RVL Pharmaceuticals is committed to improving patients' lives by developing and commercializing innovative eyecare and medical aesthetics products.

• Founded: No information is available.

• Founder: No information is available.

• Key People:

• Brian Markison: Chairman of the Board and Chief Executive Officer

• James Schaub: Executive Vice President & Chief Operating Officer

• Jarret Miller: Executive Vice President, Human Resources

• Headquarters: 400 Crossing Boulevard, Bridgewater, NJ 08807, USA; 3 Dublin Landings, North Wall Quay, Dublin 1, Ireland

• Number of Employees: No information is available.

• Revenue: No information is available.

• Known For: Specializing in the commercialization and development of eyecare and medical aesthetics products, specifically for underserved markets. Renowned for their product Upneeq®, the first FDA-approved non-surgical treatment for acquired blepharoptosis in adults.

Products

• Upneeq® (oxymetazoline hydrochloride ophthalmic solution), 0.1%

• Description: Upneeq is a non-surgical treatment for acquired blepharoptosis, or low-lying eyelids, in adults.

• Key Features:

• FDA-approved.

• Non-surgical solution for ptosis.

• Aimed at improving the quality of life for patients with low-lying eyelids.

Recent Developments

• New Products Launched: No information is available.

• New Features Added to Existing Products:

• Ongoing development of a second-generation formulation of Upneeq, alongside potential label expansion.

• New Partnerships and Developments:

• In November 2023, RVL Pharmaceuticals completed financial restructuring backed by Athyrium, which provided capital to support long-term growth and exchanged outstanding debt into equity for certain reorganized entities.

• Planned cancellation of RVL Pharmaceuticals plc's public equity in 2024 post-reorganization.

• Emergence from Chapter 11 restructuring on November 22, 2023, with continued strategic focus on Upneeq's commercialization and further development of innovative ocular solutions.

Note: RVL Pharmaceuticals has been actively pursuing strategic initiatives to address significant unmet needs in the eyecare sector through its current and pipeline products.

For additional information, please visit their company website or contact RVL Pharmaceuticals directly through their main office in Bridgewater, NJ, or their Dublin office in Ireland.